Provided by Tiger Fintech (Singapore) Pte. Ltd.

Global Partners LP

51.90
+0.79001.55%
Post-market: 51.900.00000.00%16:04 EDT
Volume:21.39K
Turnover:1.11M
Market Cap:1.76B
PE:16.59
High:52.41
Open:51.53
Low:51.50
Close:51.11
Loading ...

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

PR Newswire
·
01 May

Resmed Inc (RMD): Jim Cramer Says “Remarkable Stock” — Did GLP-1 Drugs Just Hand It a Lifeline?

Insider Monkey
·
01 May

Aon (NYSE:AON) Unveils Data-Driven GLP-1 Initiative For Workforce Health Improvement

Simply Wall St.
·
01 May

RWA Perpetual Product Crisis: Why is the GLP Model Doomed to Fail RWA Perpetual?

Blockbeats
·
30 Apr

Aon Unveils First Workforce-Focused Analysis on GLP-1s: Medications and Holistic Support Can Transform Workforce Health and Bend the Cost Curve

PR Newswire
·
30 Apr

GLP J-REIT Announces Strategic Asset Sale to Boost Dividends

TIPRANKS
·
30 Apr

GLP J-REIT Revises Forecasts Upward Following Asset Sale

TIPRANKS
·
30 Apr

Hims & Hers stock jumps on Novo Nordisk GLP-1 partnership

Yahoo Finance
·
29 Apr

Jim Cramer on Eli Lilly and Company (LLY): “Riding the wave of GLP-1 success” – Ready to Rebound After a Rare Miss

Insider Monkey
·
29 Apr

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

GlobeNewswire
·
29 Apr

PepsiCo CEO was grilled about GLP-1s by a 13-year-old on his Q1 conference call

Fortune
·
29 Apr

Global Partners Declares First-Quarter 2025 Cash Distribution of $0.7450 on Common Units

Business Wire
·
25 Apr

Press Release: Global Partners LP to Host First-Quarter 2025 Financial Results Conference Call on May 8, 2025

Dow Jones
·
24 Apr

Northstrive Biosciences Announces Positive FDA Response Supporting A Submission of IND for a Phase 2 Clinical Trial for EL-22 in Combination with GLP-1 Receptor Agonist for Obesity Treatment

GlobeNewswire
·
24 Apr

Lexaria Bioscience: A Key Player in the Future of Oral GLP-1 Drugs

TIPRANKS
·
23 Apr

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

ACCESS Newswire
·
23 Apr

MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential

PR Newswire
·
22 Apr

Eli Lilly & Co: Strong Growth Potential in GLP-1 Obesity Market with Positive Financial Outlook

TIPRANKS
·
22 Apr

Buy Rating for Structure Therapeutics: Aleniglipron’s Competitive Edge in the Oral GLP-1 Market

TIPRANKS
·
22 Apr

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

Business Wire
·
21 Apr